Register

Downloads / CME Credit

Chair & Presenters

David L. Rimm, MD, PhD
Chair
David L. Rimm, MD, PhD
Yale University School of Medicine
New Haven, Connecticut
Luis A. Diaz, MD
Presenter
Luis A. Diaz, MD
Memorial Sloan Kettering Cancer Center
New York, New York
Lynette M. Sholl, MD
Presenter
Lynette M. Sholl, MD
Brigham and Women’s Hospital
Harvard Medical School
Boston, Massachusetts

Location

Gaylord National
Room: National Harbor 10-11
201 Waterfront Street
National Harbor, MD 20745

Agenda

6:30 PM Registration and Dinner

7:00 PM Welcome and Introductions: David L. Rimm, MD, PhD

7:05 PM Master Class #1: Luis A. Diaz, MD
Immuno-Oncology as a New Tool in the Cancer Treatment Arsenal: Understanding the Basics and Implications for Pathologists

7:25 PM Master Class #2: David L. Rimm, MD, PhD and Lynette M. Sholl, MD
PD-L1 Expression and Other Current Predictive Biomarkers for Cancer Immunotherapy: The Evidence

7:55 PM Practicum: Lynette M. Sholl, MD, Luis A. Diaz, MD, and David L. Rimm, MD, PhD
PD-L1 Expression and Other Current Predictive Biomarkers for Cancer Immunotherapy: Clinical Experience, Practicalities, and Recommendations

8:15 PM Master Class #3: David L. Rimm, MD, PhD
New and Emerging Directions in Biomarker Development for Cancer Immunotherapy: How Can We Do Better?

8:25 PM Reflections and Conclusions: David L. Rimm, MD, PhD

8:30 PM Adjourn

CME Information

Activity Description & Educational Objectives

Novel cancer immunotherapies are showing remarkable clinical activity in an increasing range of solid tumors and hematologic malignancies. As the immuno-oncology (IO) landscape continues to expand, there is a growing need for biomarkers to help guide the identification of patients who are most likely to benefit from these therapies. Pathologists play an important role in cancer immunotherapy patient selection through their involvement in biomarker testing. In this unique Master Class and Practicum for pathologists, top experts examine the evolving role of IO and what this means for pathologists, exchange views on the practicalities and challenges in immunotherapy biomarker testing, and assess opportunities for further development of novel tools for predicting benefit from immunotherapies.

Upon completion of this activity, participants should be better able to:

Target Audience

This activity has been designed to meet the educational needs of pathologists and other professionals interested in the development of biomarkers for cancer immunotherapies and their applications in the practice of pathology and laboratory medicine.

Requirements for Successful Completion

In order to receive credit, participants must attend the live activity and complete the request for credit. There are no prerequisites and there is no fee to participate in this activity or to receive CME credit. Statements of Credit are awarded upon completion of the request for credit at the end of the post-test.

Media: Symposium
Release and Expiration Date: October 9, 2017
Time to Complete: 90 minutes

Faculty & Disclosure / Conflict of Interest Policy

Before the activity, all faculty and anyone who is in a position to have control over the content of this activity and their spouse/life partner will disclose the existence of any financial interest and/or relationship(s) they might have with any commercial interest producing healthcare goods/services to be discussed during their presentation(s): honoraria, expenses, grants, consulting roles, speakers bureau membership, stock ownership, or other special relationships. Presenters will inform participants of any off-label discussions. All identified conflicts of interest are thoroughly vetted by Medical Learning Institute, Inc. for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.

The associates of Medical Learning Institute, Inc., the accredited provider for this activity, and PVI, PeerView Institute for Medical Education do not have any financial relationships or relationships to products or devices with any commercial interest related to the content of this CME activity during the past 12 months.

Chair

David L. Rimm, MD, PhD
Professor of Pathology and Medicine (Medical Oncology)
Director, Yale Pathology Tissue Services
Yale University School of Medicine
New Haven, Connecticut

Presenters

Luis A. Diaz, MD
Head, Division of Solid Tumor Oncology
Memorial Sloan Kettering Cancer Center
New York, New York

Lynette M. Sholl, MD
Associate Pathologist
Brigham and Women’s Hospital
Associate Professor
Harvard Medical School
Boston, Massachusetts

Medical Director

Kadrin Wilfong, MD
PVI, PeerView Institute for Medical Education

Disclaimer

The information provided at this CME activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a healthcare provider relative to diagnostic and treatment options of a specific patient's medical condition. Recommendations for the use of particular therapeutic agents are based on the best available scientific evidence and current clinical guidelines. No bias towards or promotion for any agent discussed in this program should be inferred.

Providership, Credit & Support

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Medical Learning Institute, Inc. and PVI, PeerView Institute for Medical Education. The Medical Learning Institute, Inc. is accredited by the ACCME to provide continuing medical education for physicians.

The Medical Learning Institute, Inc. designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Providership

This CME activity is jointly provided by Medical Learning Institute, Inc. and PVI, PeerView Institute for Medical Education.

Support

This activity is supported through independent educational grants from AstraZeneca and Bristol-Myers Squibb.

Disclosure of Unlabeled Use

The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use.

No endorsement of unapproved products or uses is made or implied by coverage of these products or uses in our reports. No responsibility is taken for errors or omissions in reports.

Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings.